2-Methoxyestradiol as a potential cytostatic drug in gliomas?

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 1, 2009, Pages 55-65

  Kirches, Elmar ^a   Warich Kirches, M ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Institute of Pathology   (Germany)

Author keywords

2 methoxyestradiol; Chemotherapy; Glioblastoma multiforme; Glioma; Vasculature

Indexed keywords

2 METHOXYESTRADIOL; ALKYLATING AGENT; BEVACIZUMAB; CANCER ANTIBODY; CASPASE 8; DOCETAXEL; IRINOTECAN; NITROSOUREA; PIMONIDAZOLE; PROTEIN P53; TEMOZOLOMIDE; THALIDOMIDE; VATALANIB; 2-METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ESTRADIOL; TUBULIN MODULATOR;

ADJUVANT THERAPY; ANEMIA; ANGIONEUROTIC EDEMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE ARREST; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DIARRHEA; DNA ALKYLATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME ACTIVATION; FATIGUE; GENETIC PREDISPOSITION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MULTIPLE MYELOMA; NONHUMAN; OVERALL SURVIVAL; RADIATION DOSE; RECURRENT CANCER; REVIEW; SIDE EFFECT; SURVIVAL TIME; TREATMENT FAILURE; TUMOR VASCULARIZATION; WEIGHT REDUCTION; ANIMAL; DRUG EFFECT; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; ESTRADIOL; GLIOMA; HUMANS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 61749090805     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009787047725     Document Type: Review

References (79)

1. Ohgaki, H.; Kleihues, P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol., 2007, 170, 1445.
2. Ohgaki, H.; Kleihues, P. Epidemiology and etiology of gliomas. Acta Neuropathol., 2005, 109, 93.
3. Neglia, J.P.; Meadows, A.T.; Robison, L.L.; Kim, T.H.; Newton, W.A.; Ruymann, F.B.; Sather, H.N.; Hammond, G.D. N. Second neoplasms after acute lymphoblastic leukemia in childhood. Engl. J. Med., 1991, 325, 1330.
4. Walter, A.W.; Hancock, M.L.; Pui, C.H.; Hudson, M.M.; Ochs, J.S.; Rivera, G.K.; Pratt, C.B.; Royett, J.M.; Kun, L.E. J. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J. Clin. Oncol., 1998, 16, 3761.
5. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, G.; Eisenhauer, E.; Mirimanoff, R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352, 987.
6. Mirimanoff, R.O.; Gorlia, T.; Mason, W.; Van den Bent, M.J.; Kortmann, R.D.; Fisher, B.; Reni, M.; Brandes, A.A.; Curschmann, J.; Villa, S.; Cairncross, G.; Allgeier, A.; Lacombe, D.; Stupp, R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981-NCIC CE3 phase III randomized trial. J. Clin. Oncol., 2006, 24, 2563.
7. Stewart, L.A. Chemothertapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet, 2002, 359, 1011.
8. Hegi, M.E.; Diserens, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.; Mason, W.; Mariani, L.; Bromberg, J.E.C.; Hau, P.; Mirimanoff, R.O.; Cairncross, G.; Janzer, R.C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl. J. Med., 2005, 352, 997.
9. Tolcher, A.W.; Gerson, S.L.; Denis, L.; Geyer, C.; Hammond, L.A.; Patnaik, A.; Goetz, A.D.; Schwartz, G.; Edwards, T.; Reyderman, L.; Statkevich, P.; Cutler, D.L.; Rowinsky, E.K. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer, 2003, 88, 1004.
10. Curran, W.J.Jr.; Scott, C.B.; Horton, J.; Nelson, J.S.; Weinstein, A.S.; Fischbach, A.J.; Chang, C.H.; Rotman, M.; Asbell, S.O.; Krisch, R.E.; Nelson, D.E. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl. Cancer Inst., 1993, 85, 704.
11. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 1971, 285, 1182.
12. Gimbrone, M.A.Jr.; Leapman, S.B.; Cotran, R.S.; Folkman, J. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med., 1972, 136, 261.
13. D'Amato, R.J.; Loughnan, M.S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA, 1994, 91, 4082.
14. Fine, H.A.; Figg, W.D.; Jaeckle, K.; Wen, P.Y.; Kyritsis, A.P.; Loeffler, J.S.; Levin, V.A.; Black, P.M.; Kaplan, R.; Pluda, J.M.; Yung, W.K. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol., 2000, 18, 708.
15. Fine, H.A.; Wen, P.Y.; Maher, E.A.; Viscosi, E.; Batchelor, T.; Lakhani, N.; Figg, W.D.; Purow, B.W.; Borkowf, C.B. Phase II trial of thalidomide and carmustine for patients with recurrent highgrade gliomas. J. Clin. Oncol., 2003, 21, 2299.
16. Salmaggi, A.; Eoli, M.; Frigerio, S.; Silviani, A.; Gelati, M.; Corsini, E.; Broggi, G.; Boiardi, A. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J. Neurooncol., 2003, 62, 297.
17. Lamszus, K.; Ulbricht, U.; Matschke, J.; Brockmann, M.A.; Fillbrandt, R.; Westphal, M. Levels of soluble vacular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin. Cancer Res., 2003, 9, 1399.
18. Conrad, C.; Friedman, H.; Reardon, D.; Provenzale, J.; Jackson, E.; Serajuddin, H.; Laurent, D.; Chen, B.; Yung, W.K.A. A phase I/II trial of single-agent PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J. Clin. Oncol., 2004, 22(14S), 1512.
19. Reardon, D.; Friedman, H.S.; Yung, W.K.A.; Brada, M.; Conrad, C.; Provenzale, J.; Jackson, E.F.; Serajuddin, H.; Laurent, D.; Reitsma, D. A phase I trial of PTK787/ZK (PTK/ZK), an oral VEGF tyrosine kinase inhibitor, in combination with either temozolomide or lumustine for patients with recurrent glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. Oncol., 2004, 23, 110.
20. Kim, K.J.; Li, B.; Houck, K.; Winer, J.; Ferrara, N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors, 1992, 7, 53.
21. Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E.2nd.; Dowell, J.M.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Wagner, M.; Bigner, D.D.; Friedman, A.H.; Friedman, H.S. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res., 2007, 13, 1253.
22. Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E.2nd.; Marcello, J.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Sampson, J.; Wagner, M.; Bailey, L.: Bigner, D.D.; Friedman, A.H.; Friedman, H.S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol., 2007, 25, 4722.
23. Martucci, C.P.; Fishman, J. Impact of continously administered catechol estrogens on uterine growth and luteinizing hormone secretion. Endocrinology, 1979, 105, 1288.
24. D'Amato, R.J.; Lin, C.M.; Flynn, E.; Folkman, J.; Hamel, E. 2-Methoxyestradiol, an endogeneous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. USA, 1994, 91, 3964.
25. Mooberry, S.L. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr. Opin. Oncol., 2003, 15, 425.
26. Chauhan, D.; Catley, L.; Hideshima, T.; Li, G.; Leblanc, R.; Gupta, D.; Sattler, M.; Richardson, P.; Schlossman, R.L.; Podar, K.; Weller, E.; Munshi, N.; Anderson, K.C. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood, 2002, 100, 2187.
27. Dingli, D.; Timm, M.; Russel, S.J.; Witzig, T.E.; Rajkumar, S.V. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. Clin. Cancer Res., 2002, 8, 3948.
28. Qanungo, S.; Basu, A.; Das, M.; Haldar, S. 2-Methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells. Oncogene, 2002, 21, 4149.
29. Huang, P.; Feng, L.; Oldham, E.A.; Keating, M.J.; Plunkett, W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature, 2000, 407, 390.
30. LaVallee, T.M.; Zhan, X.H.; Johnson, M.S.; Herbstritt, C.J.; Swartz, G.; Williams, M.S.; Hembrough, W.A.; Green, S.J., Pribluda, V.S. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res., 2003, 63, 468.
31. Carothers, A.M.; Hughes, S.A.; Ortega, D.; Bertagnolli, M.M. 2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells. Cancer Lett., 2002, 187, 77.
32. Ryschich, E.; Werner, J.; Gebhard, M.M.; Klar, E.; Schmidt, J. Angiogenesis inhibition with TNP-470, 2-methoxyestradiol, and paclitaxel in experimental pancreatic carcinoma. Pancreas, 2003, 26, 166.
33. Maran, A.; Zhang, M.; Kennedy, A.M.; Sibonga, J.D.; Rickard, D.J.; Spelsberg, T.C.; Turner, R.T. 2-methoxyestradiol induces interferone gene expression and apoptosis in osteosarcoma cells. Bone, 2002, 30, 393.
34. Golebiewska, J.; Rozwadowski, P.; Spodnik, J.H.; Knap, N.; Wakabayashi, T.; Wozniak, M. Dual effect of 2-methoxyestradiol on cell cycle events in human osteosarcoma 143B cells. Acta Biochim. Pol., 2002, 49, 59.
35. Ghosh, R.; Ott, A.M.; Seetharam, D.; Slaga, T.J.; Kumar, A.P. Cell cycle block and apoptosis induction in a human melanoma cell line following treatment with 2-methoxyestradiol: therapeutic implications ? Melanoma Res., 2003, 13, 119.
36. Djavaheri-Mergny, M.; Wietzerbin, J.; Besancon, F. 2-Methoxyestradiol induces apoptosis in Ewing sarcoma cells through mitochondrial hydrogen peroxide production. Oncogene, 2003, 22, 2558.
37. Kumar, A.P.; Garcia, G.E.; Orsborn, J.; Levin, V.A.; Slaga, T.J. 2-Methoxyestradiol interferes with NF kappa B transcriptional activity in primitive neuroectodermal brain tumors: implications for mamagement. Carcinogenesis, 2003, 24, 209.
38. Lis, A.; Ciesielski, M.J.; Barone, T.A.; Scott, B.E.; Fenstermaker, R.A.; Plunkett, R.J. 2-Methoxyestradiol inhibits proliferation of normal and neoplastic glial cells, and induces cell death, in vitro. Cancer Lett., 2004, 213, 57.
39. Chamaon, K.; Stojek, J.; Kanakis, D.; Braeuninger, S.; Kirches, E.; Krause, G.; Mawrin, C.; Dietzmann, K. Micromolar concentrations of 2-methoxyestradiol kill glioma cells by an apoptotic mechanism, without destroying their microtubule cytoskeleton. J. Neurooncol., 2005, 72, 11.
40. Zou, H.; Zhao, S.; Zhang, J.; Lv, G.: Zhang, X.; Yu, H.; Wang, H.; Wang, L. Enhanced radiation-induced cytotoxic effect by 2-ME in glioma cells is mediated by induction of cell cycle arrest and DNA damage via activation of ATM pathways. Brain Res., 2007, 1185, 231.
41. Braeuninger, S.; Chamaon, K.; Kropf, S.; Mawrin, C.; Wiedemann, F.R.; Hartig, R.; Schoeler, S.; Dietzmann, K.; Kirches, E. Short incubation with 2-methoxyestradiol kills malignant glioma cells independent of death receptor 5 upregulation. Clin. Neuropathol., 2005, 24, 175.
42. Cicek, M.; Iwaniec, U.T.; Goblirsch, M.J.; Vrabel, A.; Ruan, M.; Clohisy, D.R.; Turner, R.R.; Oursler, M.J. 2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo. Cancer Res, 2007, 67, 10106.
43. Mabjeesh, N.J.; Escuin, D.; LaVallee, T.M.; Pribluda, V.S.; Swartz, G.M.; Johnson, M.S.; Willard, M.T.; Zhong, H.; Simons, J.W.; Giannakakou, P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell, 2003, 3, 363.
44. Attalla H.; Mäkelä, T.P.; Adlercreutz, H.; Andersson, L.C. 2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem. Biophys. Res. Commun., 1996, 228, 467.
45. Kamath, K.; Okouneva, T.; Larson, G.; Panda, D.; Wilson, L.; Jordan, M.A. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol. Cancer Ther., 2006, 5, 2225.
46. Bhati, R.; Gokmen-Polar, Y.; Sledge, G.W.Jr.; Fan, C.; Nakshatri, H.; Ketelsen, D.; Borchers, C.H.; Dial, M.J.; Patterson, C.; Klauber-DeMore, N. 2-methoxyestradiol inhibits the anaphasepromoting complex and protein translation in human breast cancer cells. Cancer Res., 2007, 67, 702.
47. Peters, J.M. The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol. Cell, 2002, 9, 931.
48. Huober, J.B.; Nakamura, S.; Meyn, R.; Roth, J.A., Mukhopadhyay, T. Oral administration of an estrogen metabolite induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 2000, 48, 1127.
49. Zou, H.; Adachi, M.; Imai, K.; Hareyama, M.; Yoshioka, K.; Zhao, S.; Shinomura, Y. 2-methoxyestradiol, an endogeneous mammalian metabolite, radiosensitizes colon carcinoma cells through c-Jun NH2-terminal kinase activation. Clin. Cancer Res., 2006, 12, 6532.
50. Casarez, E.V.; Dunlap-Brown, M.E.; Conaway, M.R.; Amorino, G.P. Radiosensitization and modulation of p44/42 mitogenactivated protein kinase by 2-Methoxyestradiol in prostate cancer models. Cancer Res., 2007, 67, 8316.
51. Escuin, D.; Kline, E.R.; Giannakakou, P. Both microtubulestabilizing and microtubule-destabilizing drugs inhibit hypoxiainducible factor-1.. accumulation and activity by disrupting microtubule finction. Cancer Res., 2005, 65, 9021.
52. Chakravarti, A.; Zhai, G.; Suzuki, Y.; Sarkesh, S.; Black, P.M.; Muzikansky, A.; Loeffler, J.S. J. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. Clin. Oncol., 2004, 22, 1926.
53. Nagai, S.; Washiyama, K.; Kurimoto, M.; Takaku, A.; Endo, S.; Kumanishi, T. Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J. Neurosurg., 2002, 96, 909.
54. Giese, A.; Bjerkvig, R.; Berens, M.E.; Westphal, M. Cost of migration: invasion of malignant gliomas and implication for treatment. J. Clin. Oncol., 2003, 21, 1624.
55. Hoelzinger, D.B.; Mariani, L.; Weis, J.; Woyke, T.; Berens, T.J.; McDonough, W.S.; Sloan, A.; Coons, S.W.; Berens, M.E. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia, 2005, 7, 7.
56. Lefranc, F.; Brotchi, J.; Kiss, R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol., 2005, 23, 2411.
57. Kanzawa, T.; Bedwell, J.; Kondo, Y.; Kondo, S.; Germano, I.M. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J. Neurosurg., 2003, 99, 1047.
58. Kanzawa, T.; Germano, I.M.; Komata, T.; Ito, H.; Kondo, Y.; Kondo, S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ., 2004, 11, 448.
59. Takeuchi, H.; Kanzawa, T.; Kondo, Y.; Kondo, S. Inhibition of platelet-derived growth factor signalling induces autophagy in malignant glioma cells. Br. J. Cancer, 2004, 90, 1069.
60. Roos, W.P.; Batista, I.F.; Naumann, S.C.; Wick, W.; Weller, M.; Menck, C.F.; Kaina, B. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene, 2007, 26, 186.
61. Chen, Y.; McMillan-Ward, E.; Kong, J.; Israels, S.J.; Gibson, S.B. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ., 2008, 15, 171.
62. Kang, S.H.; Cho, H.T.; Devi, S.; Zhang, Z.; Escuin, D.; Liang, Z.; Mao, H.; Brat, D.J.; Olson, J.J.; Simons, J.W.; LaVallee, T.M.; Giannakakou, P.; Van Meir, E.G.; Shim, H. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res., 2006, 66, 11991.
63. Barker, M.; Hoshino, T.; Gurcay, O.; Wilson, C.B.; Nielsen, S.L.; Downie, R.; Eliason, J. Development of an animal brain tumor model and its response to therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res., 1973, 33, 976.
64. Sasse, R.; Glyn, M.C.; Birkett, C.R.; Gull, K. Acetylated alphatubulin in Physarum: immunological characterization of the isotype and its usage in particular microtubular organelles. J. Cell Biol., 1987, 104, 41.
65. James, J.; Murry, D.J.; Treston, A.M.; Storniolo, A.M.; Sledge, G.W.; Sidor, C.; Miller, K.D. Phase I safety, pharmakokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest. New Drugs, 2007, 25, 41.
66. Dahut, W.L.; Lakhani, N.J.; Gulley, J.L.; Arlen, P.M.; Kohn, E.C.; Kotz, H.; McNally, D.; Parr, A.; Nguyen, D.; Yang, S.X.; Steinberg, S.M.; Venitz, J.; Sparreboom, A.; Figg, W.D. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol. Ther., 2006, 5, 22.
67. Sweeney, C.; Liu, G.; Yiannoutsos, C.; Kolesar, J.; Horvath, D.; Staab, M.J.; Fife, K.; Armstrong, V.; Treston. A.; Sidor, C.; Wilding, G. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmakokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin. Cancer Res., 2005, 11, 6625.
68. Rajkumar, S.V.; Richardson, P.G.; Lacy, M.Q.; Dispenzieri, A.; Greipp, P.R.; Witzig, T.E.; Schlossman, R.; Sidor, C.F.; Anderson, K.C.; Gertz, M.A. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin. Cancer Res., 2007, 13, 6162.
69. Kirkpatrick, J.; Desjardins, A.; Quinn, J.; Rich, J.; Vredenburgh, J.; Sathornsumetee, S.; Guruangan, S.; Sidor, C.; Friedman, H.; Reardon, D. Phase II open-label, safety, pharmacokinetic and efficacy ministered orally to patients with recurrent glioblastoma multiforme. J. Clin. Oncol., 2007, 25(18S), 2065.
70. Cushman, M.; He, H.M.; Katzenellenbogen, J.A.; Lin, C.M.; Hamel, E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogeneous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J. Med. Chem., 1995, 38, 2041.
71. Cushman, M.; He, H.M.; Katzenellenbogen, J.A.; Varma, R.K.; Hamel, E.; Lin, C.M.; Ram, S.; Sachdeva, Y.P. Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth. J. Med. Chem., 1997, 40, 2323.
72. Cushman, M.; Mohanakrishnan, A.K.; Hollingshead, M.; Hamel, E. The effect of exchanging various substituents at the 2-position of 2-methoxyestradiol on cytotoxicity in human cancer cell cultures and inhibition of tubulin polymerization. J. Med. Chem., 2002, 45, 4748.
73. Rao, P.N.; Cessac, J.W.; Boyd, J.W.; Hanson, A.D.; Shah, J. Synthesis and antimitotic activity of novel 2-methoxyestradiol analogs - Part II. Siteroids, 2008, 73, 158.
74. Rao, P.N.; Cessac, J.W.; Boyd, J.W.; Hanson, A.D.; Shah, J. Synthesis and antimitotic activity of novel 2-methoxyestradiol analogs - Part III. Steroids, 2008, 73, 171.
75. Edsall, A.B.; Mohanakrishnan, A.K.; Yang, D.; Fanwick, P.E.; Hamel, E.; Hanson, A.D.; Agoston, G.E.; Cushman, M. Effects of altering the electronics of 2-methoxyestradiol, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization. J. Med. Chem., 2004, 47, 5126.
76. Agoston, G.E.; Shah, J.H.; LaVallee, T.M.; Zhan, X.; Pribluda, V.S.; Treston, A.M. Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol. Bioorg. Med. Chem., 2007, 15, 7524.
77. Edsall, A.B.; Agoston, G.E.; Treston, A.M.; Plum, S.M.; McClanahan, R.H.; Lu, T.S.; Song, W.; Cushman, M. Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate. J. Med. Chem., 2007, 50, 6700.
78. Ireson, C.R.; Chander, S.K.; Purohit, A.; Perera, S.; Newman, S.P.; Parish, D.; Leese, M.P.; Smith, A.C.; Potter, B.V.L.; Reed, M.J. Pharmacokinetics and efficacy of 2-methoxyestradiol and 2-methoxyestradiol-bis-sulphamate in vivo in rodents. Br. J. Cancer, 2004, 90, 932.
79. Chander, S.K.; Foster, P.A.; Leese, M.P.; Newman, S.P.; Potter, B.V.L.; Purohit, A.; Reed, M.J. In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyestradiol. Br. J. Cancer, 2007, 96, 1368.